Want to see BCYC full AI Analyst Report?
BCYC Stock Chart & Stats
$5.33
-$0.24(-1.59%)
At close: 4:00 PM EST
$5.33
-$0.24(-1.59%)
Day’s Range― - ―
52-Week Range$3.92 - $9.18
Previous CloseN/A
Volume92.63K
Average Volume (3M)536.21K
Market Cap
$291.38M
Enterprise Value-$263.78M
Total Cash (Recent Filing)$559.47M
Total Debt (Recent Filing)$15.34M
Price to Earnings (P/E)―
Beta1.82
Next Earnings
Aug 06, 2026EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.15
Shares Outstanding50,373,280
10 Day Avg. Volume438,522
30 Day Avg. Volume536,212
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)0.80
Price to Sales (P/S)6.76
P/FCF Ratio-1.94
Enterprise Value/Market Cap-0.91
Enterprise Value/Revenue-4.15
Enterprise Value/Gross Profit35.02
Enterprise Value/Ebitda1.25
Forecast
1Y Price Target
$10.20Price Target Upside91.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.28
Revenue Forecast (FY)$23.68M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetVery low financial leverage reduces solvency risk and gives management runway flexibility to fund clinical programs or negotiate partnerships. Over a multi-month horizon this lowers refinancing pressure and preserves strategic optionality despite ongoing burn.
Duravelo-2 Phase 2 Clinical ProgressRobust Phase 2 signals and a favorable safety profile materially de-risk the lead Nectin-4 program. If confirmed in later stages, this can convert into durable clinical and commercial value, strengthen partner interest, and justify continued investment in development.
EphA2 Pipeline Advancement And Dose SelectionProgress across EphA2 programs—including dose selection, objective responses, and expansion into hard-to-treat indications—broadens the pipeline and reduces binary risk. Clinical validation and imaging/xenograft support increase long-term partnering and commercialization optionality.
Bears Say
High Cash BurnSustained, large negative operating and free cash flow means the company must rely on external funding to sustain operations. Over months this raises dilution risk, constrains parallel program funding, and can force prioritization of assets regardless of scientific merit.
Deeply Negative Profitability And Large LossesVery large operating losses reflect a cost base well ahead of revenue generation. Without a clear path to break-even, persistent negative profitability erodes equity, limits reinvestment capacity, and increases dependence on milestone/license structures to sustain development.
Revenue Volatility And Partner-dependent ReceiptsRevenue driven by collaborations and milestone timing is lumpy, making cash flow and runway unpredictable. Over a 2–6 month horizon this variability complicates planning, increases financing uncertainty, and heightens execution risk for concurrent trials.
Bicycle Therapeutics News
BCYC FAQ
What was Bicycle Therapeutics’s price range in the past 12 months?
Bicycle Therapeutics lowest stock price was $3.92 and its highest was $9.18 in the past 12 months.
What is Bicycle Therapeutics’s market cap?
Bicycle Therapeutics’s market cap is $291.38M.
When is Bicycle Therapeutics’s upcoming earnings report date?
Bicycle Therapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 25 days.
How were Bicycle Therapeutics’s earnings last quarter?
Bicycle Therapeutics released its earnings results on Apr 30, 2026. The company reported -$0.87 earnings per share for the quarter, missing the consensus estimate of -$0.621 by -$0.249.
Is Bicycle Therapeutics overvalued?
According to Wall Street analysts Bicycle Therapeutics’s price is currently Undervalued.
Does Bicycle Therapeutics pay dividends?
Bicycle Therapeutics does not currently pay dividends.
What is Bicycle Therapeutics’s EPS estimate?
Bicycle Therapeutics’s EPS estimate is -0.56.
How many shares outstanding does Bicycle Therapeutics have?
Bicycle Therapeutics has 50,373,280 shares outstanding.
What happened to Bicycle Therapeutics’s price movement after its last earnings report?
Bicycle Therapeutics reported an EPS of -$0.87 in its last earnings report, missing expectations of -$0.621. Following the earnings report the stock price went down -0.211%.
Which hedge fund is a major shareholder of Bicycle Therapeutics?
Currently, no hedge funds are holding shares in BCYC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bicycle Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.20 (91.37% Upside)
$10.20 (91.37% Upside)
Hedge Fund Trend
Increased
By 63.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $59.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.5%
Last 30 Days ▲ 17.2%
Last 30 Days ▲ 17.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.48%
12-Months-Change
Fundamentals
Return on Equity
-35.74%
Trailing 12-Months
Asset Growth
-26.19%
Trailing 12-Months
Company Description
Bicycle Therapeutics
Bicycle Therapeutics plc, founded in 2009 and based in Cambridge, UK, is a clinical-stage biopharmaceutical company. Its core mission is to create innovative therapeutic classes for diseases currently lacking effective treatments. The company's leading investigational product, BT1718, is a Bicycle Toxin Conjugate (BTC) that is undergoing Phase I/IIa clinical trials. This candidate is engineered to target tumors specifically expressing Membrane Type 1 matrix metalloprotease. Other oncology assets in their pipeline include BT5528, also a BTC in Phase I/II studies, which targets EphA2, and BT8009, currently in Phase I/II clinical development, designed to target Nectin-4. Beyond cancer, Bicycle Therapeutics is advancing THR-149, a plasma kallikrein inhibitor that has completed Phase II clinical trials for the treatment of diabetic macular edema. Their portfolio also includes Bicycle tumor-targeted immune cell agonists (TICAs) such as BT7480, which targets Nectin-4, and BT7455, an EphA2/CD137 TICA presently in preclinical development. The company actively fosters collaborations with various biopharmaceutical entities and organizations, broadening its development efforts into therapeutic areas like anti-infectives, cardiovascular conditions, ophthalmology, and respiratory illnesses. Notable partnerships include a clinical trial and license agreement with Cancer Research Technology Limited and Cancer Research UK. They also maintain research collaborations with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund. Furthermore, a significant discovery collaboration and license agreement with Genentech is in place for the identification and development of Bicycle peptides for multiple immuno-oncology targets.
BCYC Stock 12 Month Forecast
Average Price Target
$10.20
▲(91.37% Upside)
Technical Analysis
Ownership Overview
23.05% Insiders
3.43% Mutual Funds
0.20% Other Institutional Investors
72.27% Public Companies and
Individual Investors